Compare ODC & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ODC | RAPP |
|---|---|---|
| Founded | 1941 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 1994 | 2024 |
| Metric | ODC | RAPP |
|---|---|---|
| Price | $86.13 | $29.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $63.04 |
| AVG Volume (30 Days) | 110.2K | ★ 420.4K |
| Earning Date | 10-08-2026 | 11-05-2026 |
| Dividend Yield | ★ 1.05% | N/A |
| EPS Growth | ★ 50.45 | 24.34 |
| EPS | ★ 1.69 | N/A |
| Revenue | ★ $493,844,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $50.56 | ★ N/A |
| Revenue Growth | ★ 1.70 | N/A |
| 52 Week Low | $45.61 | $23.75 |
| 52 Week High | $107.00 | $52.93 |
| Indicator | ODC | RAPP |
|---|---|---|
| Relative Strength Index (RSI) | 39.45 | 22.98 |
| Support Level | $84.97 | $26.08 |
| Resistance Level | $94.03 | $31.57 |
| Average True Range (ATR) | 3.46 | 1.63 |
| MACD | -0.42 | -0.13 |
| Stochastic Oscillator | 45.47 | 10.27 |
Oil-Dri Corp of America develops, manufactures, and markets sorbent products made predominantly from clay. Its absorbent offerings, which draw liquid up, include cat litter, floor products, toxin control substances for livestock, and agricultural chemical carriers. The company has two segments based on the different characteristics of two primary customer groups, namely the Retail and Wholesale Products Group, which derives maximum revenue, and the Business-to-Business Products Group. The company's products are sold under various brands such as Cat's Pride, Jonny Cat, Amlan, Agsorb, Verge, Pure-Flo, and Ultra-Clear.
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.